FREMONT, Calif., March 11 /PRNewswire-FirstCall/ -- Vermillion, Inc (Pink Sheets: VRML) today announced that Gail Page, Vermillion's Chief Executive Officer, will be presenting at the Roth 22nd Annual OC Growth Stock Conference in Laguna Niguel.
The presentation is scheduled for Monday, March 15, 2010 at 2:00 p.m. Pacific. The presentation will be web cast and is available through the investor relations section of our web site at www.vermillion.com.
About the OVA1 Test
The OVA1 Test is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and a proprietary algorithm to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.
SOURCE Vermillion, Inc.Back to top
|SOURCE Vermillion, Inc.|
Copyright©2010 PR Newswire.
All rights reserved